Long-term outcomes of catheter ablation of ventricular tachycardia in patients with structural heart disease

Background: Catheter ablation of ventricular tachycardia (VT) is feasible. However, the long-term outcomes for different underlying diseases have not been well defined. Methods: Eighty-eight consecutive patients who underwent catheter ablation of VT using a three-dimensional mapping system were anal...

Full description

Bibliographic Details
Main Authors: Masahiko Goya, MD, Masato Fukunaga, MD, Ken-ichi Hiroshima, MD, Kentaro Hayashi, MD, Yu Makihara, MD, Michio Nagashima, MD, Yoshimori An, MD, Seiji Ohe, MD, Kennosuke Yamashita, MD, Kenji Ando, MD, Hiroyoshi Yokoi, MD, Masashi Iwabuchi, MD, Kouji Katayama, Tomoaki Ito, Harushi Niu
Format: Article
Language:English
Published: Wiley 2015-02-01
Series:Journal of Arrhythmia
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S188042761400101X
Description
Summary:Background: Catheter ablation of ventricular tachycardia (VT) is feasible. However, the long-term outcomes for different underlying diseases have not been well defined. Methods: Eighty-eight consecutive patients who underwent catheter ablation of VT using a three-dimensional mapping system were analyzed. The primary endpoint was any VT or ventricular fibrillation (VF) recurrence. Secondary endpoints were a composite of death or any VT/VF recurrence. Underlying heart diseases were remote myocardial infarction (remote MI) in 51 patients and non-ischemic cardiomyopathy in 37 (arrhythmogenic right ventricular cardiomyopathy [ARVC] in 18 patients, and dilated cardiomyopathy [NIDCM] in 19). Results: Acute success was achieved in 82 of 88 (93%) patients. During a follow-up period of 39.2±4.6 months, VT recurred in 26 of 87 (30%), and VT/VF recurrence or death occurred in 39 of 87 (45%) patients. ARVC had better outcomes than NIDCM for the primary (p<0.05) and secondary endpoints (p<0.05). Remote MI-VT revealed a midrange outcome. Conclusions: The long-term outcomes after catheter ablation of VT varied according to the underlying heart disease. ARVC-VT ablation was associated with better long-term prognosis than NIDCM. Remote MI-VT demonstrated a midrange outcome.
ISSN:1880-4276